Vaccine (Adenoviral vector) · Gene replacement · developed by MeiraGTx, LLC
Cetoquagene parvec is a replication-deficient recombinant adenovirus gene therapy encoding human aquaporin-1, a water channel protein. After transfection of salivary glands, it directs hAQP1 expression in the membranes of salivary secretory cells, which may increase saliva production. It is studied in head and neck cancer and in radiation-induced xerostomia and salivary hypofunction.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02446249 | Phase 1 | Squamous Cell Head and Neck Cancer | Completed | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Radiation Induced XerostomiaSalivary HypofunctionSquamous Cell Head and Neck Cancer
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →